Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

It was approved by the MHRA on the back of the CheckMate-9ER trial, which compared the combination with Pfizer’s Sutent (sunitinib) in 651 patients with advanced RCC and found that it reduced ...

Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...

Pharmac has today announced their decision to fund six medicines for cancer, including a combination treatment, and one ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac's decision to fund medicines ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Over the last 7 days, the United States market has experienced a 2.5 ...

The deep response rate was 53%, and the objective response rate was 86%. The combination of neoadjuvant chemoimmunotherapy (CIT) with response-guided chemoradiotherapy (CRT) may improve survival ...

The average life expectancy was 80.3 years among men with a total motile sperm count over 120 million, compared with 77.6 years among men with a total motile sperm count ranging from >0 to 5 million.